. 2021 Dec 13;14(12):1297. doi: 10.3390/ph14121297

Table 1.

Description of studies and populations included in formal analyses.

First Author and Year	Sample ³	Cerebrolysin Regimen		Comparator	Initiation Window	Endpoint	Countries	Baseline NIHSS
Ladurner, 2005 [21]	n = 146	50 mL/day for 121 days		Placebo (0.9% saline)	Within 24 h	CNS at day 21	Austria, Czech Republic, Hungary	CNS ¹ 6.9 ¹ 6.7 ¹ NIHSS 9.2 ⁵ 9.6 ⁵
Skvortsova, 2004 [22]	n = 60	10 or 50 mL/day for 10 days		Placebo (0.9% saline)	Within 12 h	MRI infarct volume at day 30	Russia, Romania	13.1 ^1,4 12.6 ¹
		+100 mg ASA/day for 10 days
		+250 mg ASA/day for 90 days +pentoxifylline (days 1–21: 300 mg, days 22–90: 800 mg/day)
Shamalov, 2010 [23]	n = 47	50 mL/day for 10 days		Placebo (0.9% saline)	Within 12 h	MRI infarct volume at day 30	Russia	7.7 ¹ 8.6 ¹
Shamalov, 2010 [23]	n = 47	+100 mg ASA/day for 10 days			Within 12 h	MRI infarct volume at day 30	Russia	7.7 ¹ 8.6 ¹
Gharagozli, 2017 [17]	n = 100	Day 1–7: 30 mL/day Week 2–4: 10 mL/day, 5 days/week		Placebo (0.9% saline)	Within 18 h	NIHSS at day 30	Iran	9.1 ¹ 11.1 ¹
Gharagozli, 2017 [17]	n = 100	+ basic therapy			Within 18 h	NIHSS at day 30	Iran	9.1 ¹ 11.1 ¹
Heiss, 2012 [18]	n = 1070	Cerebrolysin 30 mL/day for 10 days		Placebo (0.9% saline)	Within 12 h	Composite of NIHSS, mRS, BI at day 90	China, Hong Kong, South Korea, Myanmar	9 ² 9 ²
Heiss, 2012 [18]	n = 1070	+100 mg ASA/day for 90 days			Within 12 h	Composite of NIHSS, mRS, BI at day 90	China, Hong Kong, South Korea, Myanmar	9 ² 9 ²
Lang, 2013 [19]	n = 119	Cerebrolysin 30 mL/day for 10 days		Placebo (0.9% saline)	Immediately after rt-PA infusion	mRS at day 90	Austria, Croatia, Czech Republic, Slovakia, Slovenia	12.3 ¹ 11.0 ¹
Lang, 2013 [19]	n = 119	+rt-PA over 60 min			Within 3 h	mRS at day 90	Austria, Croatia, Czech Republic, Slovakia, Slovenia	12.3 ¹ 11.0 ¹
Amiri-Nikpour, 2014 [24]	n = 46	Cerebrolysin 30 mL/day for 10 days		Placebo	Within 6–24 h	NIHSS at day 30, 60, 90	Iran	14 ² 14 ²
Amiri-Nikpour, 2014 [24]	n = 46	+100 mg ASA			Within 6–24 h	NIHSS at day 30, 60, 90	Iran	14 ² 14 ²
Muresanu, 2016 [9]	n = 208	Cerebrolysin 30 mL/day for 21 days		Placebo	Within 24–72 h	ARAT at day 90	Romania, Ukraine, Poland	9.1 ¹ 9.2 ¹
Muresanu, 2016 [9]	n = 208	+ basic therapy			Within 24–72 h	ARAT at day 90	Romania, Ukraine, Poland	9.1 ¹ 9.2 ¹
Guekht, 2015 [20]	n = 240	Cerebrolysin 30 mL/day for 21 days		Placebo	Within 24–72 h	ARAT at day 90	Russia	7.5 ¹ 6.8 ¹
Chang, 2016 [25]	n = 70	30 mL/day for 21 days		Placebo (0.9% saline)	Within 7 days	FMA-T at day 29	Korea	8.4 ¹ 7.0 ¹
Xue, 2016 [26]	n = 84	Cerebrolysin 30 mL/day for 10 days		Placebo	Within 12 h	NIHSS and BI Day 30	China	13.3 ¹ 12.7 ¹
		Cerebrolysin 30 mL/day for 10 days		NBP
		+basic therapy
Stan, 2017 [10]	n = 84	Cerebrolysin 30 mL/day for 10 days	Placebo		Within 48 h	NIHSS at Day 30	Romania	8.9 ¹ 7.8 ¹

¹ Means (Cerebrolysin vs. placebo), ² medians (Cerebrolysin vs. placebo), ³ all randomized groups, ⁴ 50 mL group ⁵ No NIHSS available, NIHSS derived from CNS using validated a conversion model [27].